Get the Stockscreener App
0.00
100.00%
-7.15
G 1 Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
See More
Previous Close:
$7.15
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$377.22M
Revenue:
$58.20M
Net Income/Loss:
$-44.77M
P/E Ratio:
0.00
EPS:
-1.69
Net Cash Flow:
$-37.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$7.19
G 1 Therapeutics Inc Stock (GTHX) Company Profile
Name
G 1 Therapeutics Inc
Sector
Industry
Phone
919-213-9835
Address
700 PARK OFFICES DRIVE, RESEARCH TRIANGLE PARK, NC
Compare GTHX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GTHX
G 1 Therapeutics Inc
|
0.00 | 377.22M | 58.20M | -44.77M | -37.54M | -0.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
G 1 Therapeutics Inc Stock (GTHX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-03-23 | Reiterated | Needham | Buy |
| Nov-04-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Sep-30-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-17-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-26-20 | Initiated | ROTH Capital | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-08-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-07-19 | Initiated | B. Riley FBR | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-20-18 | Initiated | Raymond James | Strong Buy |
| Nov-08-18 | Reiterated | Needham | Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-29-18 | Initiated | H.C. Wainwright | Buy |
| May-18-18 | Reiterated | Needham | Buy |
View All
G 1 Therapeutics Inc Stock (GTHX) Latest News
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program - Business Wire
Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q3 Revenue $12.3M, vs. Street Est of $14.2M - Marketscreener.com
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer - Marketscreener.com
G1 Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $12.9M, vs. Street Est of $11.4M - Marketscreener.com
Insider Sell: G1 Therapeutics - Marketscreener.com
G1 Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics - Yahoo Finance
Needham Adjusts Price Target on G1 Therapeutics to $32 From $42, Reiterates Buy Rating - Marketscreener.com
HC Wainwright Adjusts G1 Therapeutics Price Target to $57 From $67, Maintains Buy Rating - Marketscreener.com
G1 Therapeutics Says Study Confirms Myelosuppression Risk In Patients Getting Chemotherapy for Lung Cancer - Marketscreener.com
G1 Therapeutics Says Phase 2 Trial Shows Objective Response Rate of 40% in Patients With Bladder Cancer - Marketscreener.com
Needham Adjusts Price Target on G1 Therapeutics to $31 From $32, Maintains Buy Rating - Marketscreener.com
G1 Therapeutics : to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020 - Marketscreener.com
G1 Therapeutics : to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020 - Marketscreener.com
G1 Therapeutics to End Colorectal Cancer Trial of Drug Therapy; Shares Plunge - Marketscreener.com
G1 Therapeutics Says Trilaciclib Shows Potential for Improved Clinical Outcome in Phase 2 Breast Cancer Trial - Marketscreener.com
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
46,234 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Federated Hermes Inc. - Defense World
Global study predicts sharp rise in cancer rates among men by 2050 - Benefits and Pensions Monitor
Edgewise Therapeutics (EWTX) Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy - StreetInsider.com
Edgewise Therapeutics, Inc Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy - Marketscreener.com
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Benzinga
why G1 Therapeutics Inc [GTHX] is a Good Choice for Investors After New Price Target of $7.15 - The DBT News
G1 Therapeutics Inc [GTHX] Insider Perry Andrew sells 1,337 Shares - Knox Daily
G1 Therapeutics Inc: Navigating a Turbulent Year, Up -0.70% from 52-Week Low - The InvestChronicle
Acadian Asset Management LLC Increases Stake in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
Insider Selling: Perry Andrew, G1 Therapeutics Inc [GTHX] Chief Commercial Officer divested 1,337 shares - Knox Daily
Recent Insider Activity Could Benefit G1 Therapeutics Inc (GTHX) - Knox Daily
Exploring High Growth Tech Stocks in the United States for September 2024 - Simply Wall St
Pharmacosmos moves forward with G1 Therapeutics buyout - Investing.com India
GTHXG1 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - GlobeNewswire
Keeping an Eye on G1 Therapeutics Inc (GTHX) After Insider Trading Activity - Knox Daily
Panagora Asset Management Inc. Buys New Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
A company insider recently sold 1,337 shares of G1 Therapeutics Inc [GTHX]. Should You Sale? - Knox Daily
The Significance of Moving Averages in G1 Therapeutics Inc Inc. (GTHX) Price Performance - The InvestChronicle
G1 Therapeutics Inc (GTHX) gets rating Upgrade from JP Morgan - Knox Daily
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.12, a 0.28 Surge/Decline - The Dwinnex
It is Poised to be a Bull Market for G1 Therapeutics Inc (GTHX) - SETE News
G1 Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
It would be worthwhile to take a closer look at G1 Therapeutics Inc (GTHX) - US Post News
Monopar Receives Clearance to Proceed with Phase 1 - GlobeNewswire
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.09, a -0.28 Surge/Decline - The Dwinnex
Finansavisen - Finansavisen
The Potential Rise in the Price of G1 Therapeutics Inc (GTHX) following insiders activity - Knox Daily
A look into G1 Therapeutics Inc (GTHX)’s deeper side - SETE News
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose - Yahoo Finance
G 1 Therapeutics Inc Stock (GTHX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):